SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
0.00
+0.0320 (0.84%)
Apr 1, 2026, 9:42 AM EDT - Market open
SAB Biotherapeutics Market Cap
SAB Biotherapeutics has a market cap or net worth of $269.16 million as of April 1, 2026. Its market cap has increased by 1,711.38% in one year.
Market Cap
269.16M
Enterprise Value
178.51M
1-Year Change
1,711.38%
Ranking
Category
Stock Price
n/a
Market Cap Chart
Since February 9, 2021, SAB Biotherapeutics's market cap has increased from $130.75M to $269.16M, an increase of 105.85%. That is a compound annual growth rate of 15.09%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 30, 2026 | 265.64M | 49.20% |
| Dec 31, 2025 | 178.05M | 408.46% |
| Dec 31, 2024 | 35.02M | -44.79% |
| Dec 29, 2023 | 63.43M | 113.36% |
| Dec 30, 2022 | 29.73M | -91.24% |
| Dec 31, 2021 | 339.54M | 159.68% |
| Feb 9, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| NervGen Pharma | 291.52M |
| Inhibikase Therapeutics | 286.31M |
| ALX Oncology Holdings | 268.48M |
| AC Immune | 267.84M |
| Minerva Neurosciences | 267.44M |
| Protara Therapeutics | 267.18M |
| Foghorn Therapeutics | 264.15M |
| LENZ Therapeutics | 263.38M |